TherapeuticsMD, Inc. — Director's Dealing 2023

Jan 31, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TherapeuticsMD, Inc. (TXMD)
CIK: 0000025743
Period of Report: 2023-01-26

Reporting Person: Donegan Michael C (Prin. Fin. and Acctg. Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-01-26	Common Stock	M	2400	$0.00	Acquired	10010	Direct
2023-01-26	Common Stock	M	2400	$0.00	Acquired	12410	Direct
2023-01-26	Common Stock	M	1140	$0.00	Acquired	13550	Direct
2023-01-26	Common Stock	S	1648	$5.0796	Disposed	11902	Direct
2023-01-27	Common Stock	S	49	$5.09	Disposed	11853	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-01-26	Performance Stock Units	$0.00	M	2400	Disposed		Common Stock (2400)	Direct
2023-01-26	Performance Stock Units	$0.00	M	2400	Disposed		Common Stock (2400)	Direct
2023-01-26	Performance Stock Units	$0.00	M	1140	Disposed		Common Stock (1140)	Direct

Footnotes

F1: Each performance stock unit ("PSU") represents a contingent right to receive one share of issuer common stock upon settlement. On January 26, 2023, the reporting person received 5,940 shares of issuer common stock in settlement of performance stock units (PSUs).

F2: The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.01 through $5.17, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.

F4: Vesting of the PSUs was accelerated in connection with the termination of the reporting person's employment agreement without "Good Cause".